Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Ritux

Name: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Ritux
Start: 2027-02-15

February 15, 2027

Company: Adicet Bio, Inc. (ACET)
Indication: Lymphoma, Mantle Cell

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Ritux — ACET Phase 3 Readout | BioSniper